Changes in Expression of Proteoglycan Core Proteins and Heparan Sulfate Enzymes in the Developing and Adult Murine Aorta

Overview

Journal J Cardiovasc Transl Res

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2011 Apr 7

PMID 21468773

Citations 9

Authors

Neeta Adhikari

Marjorie Carlson

Ben Lerman

Jennifer L Hall

Affiliations

Soon will be listed here.

Abstract

Proteoglycan core proteins are linked to four different classes of linear sugar chains referred to as glycosaminoglycans. Heparan sulfate constitutes one of these classes of glycosaminoglycans, and has been shown to be important in developmental processes as well as disease. We designed a low-density gene expression array to identify expression levels of heparan sulfate biosynthetic enzymes and proteoglycan core proteins in the aorta of late stage embryos (E18.5) and adult mice (12 weeks). Significant changes were found in mRNA expression of proteoglycan core proteins syndecan, glypican, decorin, perlecan, and versican from development to adulthood (n = 8, p < 0.05). Immunohistochemistry revealed a striking localization of both decorin and perlecan staining to the subendothelium in adult vessels, which differed from consistent staining of the endothelium, smooth muscle, and adventitia in development. Significant differences were also identified in the expression of the heparan sulfate modifying enzymes, glururonyl C5 epimerase, 2-O and 6-O sulfotransferases, and N-deacetylase/N sulfotransferases 1-3 (n = 8, p < 0.05). In conclusion, proteoglycan core proteins and heparan sulfate biosynthetic enzymes in the aorta undergo significant changes in their expression from development to adulthood. These findings may have important biological significance in the specific cell-defined roles of proteoglycan and heparan sulfate related targets in vascular development, maintenance, and response to various perturbations.

Citing Articles

Aggrecan in Cardiovascular Development and Disease.

Koch C, Lee C, Apte S J Histochem Cytochem. 2020; 68(11):777-795.

PMID: 32870742 PMC: 7649964. DOI: 10.1369/0022155420952902.

The matrix proteins aggrecan and fibulin-1 play a key role in determining aortic stiffness.

Yasmin , Al Maskari R, Mceniery C, Cleary S, Li Y, Siew K Sci Rep. 2018; 8(1):8550.

PMID: 29867203 PMC: 5986773. DOI: 10.1038/s41598-018-25851-5.

Syndecan-1-coating of interleukin-17-producing natural killer T cells provides a specific method for their visualization and analysis.

Jaiswal A, Sadasivam M, Hamad A World J Diabetes. 2017; 8(4):130-134.

PMID: 28465789 PMC: 5394732. DOI: 10.4239/wjd.v8.i4.130.

Heparanase and Syndecan-4 Are Involved in Low Molecular Weight Fucoidan-Induced Angiogenesis.

Haddad O, Guyot E, Marinval N, Chevalier F, Maillard L, Gadi L Mar Drugs. 2015; 13(11):6588-608.

PMID: 26516869 PMC: 4663543. DOI: 10.3390/md13116588.

Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine.

Barbato E, Barton P, Bartunek J, Huber S, Ibanez B, Judge D J Cardiovasc Transl Res. 2015; 8(8):466-74.

PMID: 26453460 DOI: 10.1007/s12265-015-9657-x.

References

Adhikari N, Basi D, Townsend D, Rusch M, Mariash A, Mullegama S . Heparan sulfate Ndst1 regulates vascular smooth muscle cell proliferation, vessel size and vascular remodeling. J Mol Cell Cardiol. 2010; 49(2):287-93. PMC: 2885463. DOI: 10.1016/j.yjmcc.2010.02.022. View

Rogers C, Karnovsky M, Edelman E . Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation. 1993; 88(3):1215-21. DOI: 10.1161/01.cir.88.3.1215. View

Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Nakamura E, Ito M . Syndecan-4 deficiency impairs the fetal vessels in the placental labyrinth. Dev Dyn. 2000; 219(4):539-44. DOI: 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1081>3.0.CO;2-K. View

Clowes A, Clowes M, Gown A, Wight T . Localization of proteoheparan sulfate in rat aorta. Histochemistry. 1984; 80(4):379-84. DOI: 10.1007/BF00495421. View

Lovich M, Edelman E . Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc Natl Acad Sci U S A. 1999; 96(20):11111-6. PMC: 17995. DOI: 10.1073/pnas.96.20.11111. View

Bame K . Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology. 2001; 11(6):91R-98R. DOI: 10.1093/glycob/11.6.91r. View

Clowes A, Karnowsky M . Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977; 265(5595):625-6. DOI: 10.1038/265625a0. View

Francis D, Parish C, McGarry M, Santiago F, Lowe H, Brown K . Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circ Res. 2003; 92(8):e70-7. DOI: 10.1161/01.RES.0000071345.76095.07. View

Li J, Gong F, Hagner-McWhirter A, Forsberg E, Abrink M, Kisilevsky R . Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. J Biol Chem. 2003; 278(31):28363-6. DOI: 10.1074/jbc.C300219200. View

10.

Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F . Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A. 2002; 99(6):3657-62. PMC: 122579. DOI: 10.1073/pnas.022017899. View

11.

Segev A, Nili N, Strauss B . The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res. 2004; 63(4):603-10. DOI: 10.1016/j.cardiores.2004.03.028. View

12.

Fukai N, Kenagy R, Chen L, Gao L, Daum G, Clowes A . Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler Thromb Vasc Biol. 2009; 29(9):1356-62. PMC: 2729810. DOI: 10.1161/ATVBAHA.109.190132. View

13.

Jones E, Yuan L, Breant C, Watts R, Eichmann A . Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos. Development. 2008; 135(14):2479-88. DOI: 10.1242/dev.014902. View

14.

Ten Dijke P, Arthur H . Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007; 8(11):857-69. DOI: 10.1038/nrm2262. View

15.

MacArthur J, Bishop J, Stanford K, Wang L, Bensadoun A, Witztum J . Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007; 117(1):153-64. PMC: 1716206. DOI: 10.1172/JCI29154. View

16.

Auguste P, Javerzat S, Bikfalvi A . Regulation of vascular development by fibroblast growth factors. Cell Tissue Res. 2003; 314(1):157-66. DOI: 10.1007/s00441-003-0750-0. View

17.

Wang L, Fuster M, Sriramarao P, Esko J . Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol. 2005; 6(9):902-10. DOI: 10.1038/ni1233. View

18.

Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko J . Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim Biophys Acta. 2002; 1573(3):209-15. DOI: 10.1016/s0304-4165(02)00386-0. View

19.

Forsberg E, Kjellen L . Heparan sulfate: lessons from knockout mice. J Clin Invest. 2001; 108(2):175-80. PMC: 203035. DOI: 10.1172/JCI13561. View

20.

Zhou Z, Wang J, Cao R, Morita H, Soininen R, Chan K . Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res. 2004; 64(14):4699-702. DOI: 10.1158/0008-5472.CAN-04-0810. View